Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for VTE Prevention in Low-Risk Cancer Surgery Patients
NCT03988231Phase 4Withdrawn
- Sponsor
- University of Utah
- Start
- Jul 2021
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of enoxaparin in venous thromboembolism (VTE), sponsored by University of Utah. Planned start Jul 2021; status: withdrawn.
02
Drugs
enoxaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03988231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988231.